Results 251 to 260 of about 364,936 (336)
A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin +4 more
wiley +1 more source
Tumor evolution in lung adenocarcinoma is shaped by genetic alterations and spatial immune dynamics. By integrating whole‐exome sequencing, imaging mass cytometry, and spatial transcriptomics across two mouse models, this study reveals how mutational burden, immune infiltration, and cell–state interactions evolve during early and late carcinogenesis ...
Bo Zhu +34 more
wiley +1 more source
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia +14 more
wiley +1 more source
Biodegradable Adhesive Systems for Bio‐Integrated Applications
Biodegradable adhesives provide temporary yet reliable adhesion while degrading into safe, non‐toxic by‐products under physiological or environmental conditions. This review summarizes recent developments in physical and chemical adhesion mechanisms—including hydrogen bonding, catechol chemistry, amine‐carboxyl coupling, and emerging diazirine and urea
Won Bae Han +6 more
wiley +1 more source
No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes. [PDF]
Lennox AL +7 more
europepmc +1 more source
TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng +9 more
wiley +1 more source
PredIG: an interpretable predictor of T-cell epitope immunogenicity. [PDF]
Farriol-Duran R +5 more
europepmc +1 more source

